|
[Related PubMed/MEDLINE]
Total Number of Papers: 3786
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients. |
ALN, DCE, NAC |
| 2 |
2023 |
A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. |
CRT, LARC |
| 3 |
2023 |
A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer. |
DFS, LARC |
| 4 |
2023 |
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). |
BC, C1D15, CCCA, PLT |
| 5 |
2023 |
Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists. |
NAC |
| 6 |
2023 |
Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI. |
CE-CBBCT, DCIS, ICC, NAC |
| 7 |
2023 |
Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. |
DWI, NACT, ROI |
| 8 |
2023 |
Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. |
CRT, ESCC, HR, OS, PD-L1, RFS, Siglec-15, TCs |
| 9 |
2023 |
Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma. |
IMRT, LPS, PLPS, RT |
| 10 |
2023 |
Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case. |
FISH, ICIs, IHC, NUT, PD-L1 |
| 11 |
2023 |
Clinical significance of adjuvant chemotherapy for pathological complete response rectal cancer patients with acellular mucin pools after neoadjuvant chemoradiotherapy. |
ACT, CRT, DFS, LARC |
| 12 |
2023 |
Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. |
CI, GC/GEJC, ICIs, MPR, NACT, PD-1, PD-L1, RCTs, TRAEs |
| 13 |
2023 |
Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. |
HER2, HR, NST |
| 14 |
2023 |
Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma. |
CI, ESCC, ICIs, nabTP, OR |
| 15 |
2023 |
Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer. |
IHC, NAST, OS |
| 16 |
2023 |
CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study. |
CT, LNs, NAC |
| 17 |
2023 |
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. |
ACT, EBC, ET |
| 18 |
2023 |
Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer. |
AUC, DCE-MRI, DLR, NAC |
| 19 |
2023 |
Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast Cancer. |
AUC, BC, cN, cT, DCA, ER, NAC |
| 20 |
2023 |
Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients. |
BC, ddPCR, NACT, NGS |
| 21 |
2023 |
Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma - a phase ib/ii study. |
--- |
| 22 |
2023 |
DWI-MR and PET-CT Functional Imaging for Boost Tumor Volume Delineation in Neoadjuvant Rectal Cancer Treatment. |
DWI, GTV, LARC, MR, PET-CT |
| 23 |
2023 |
Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab for locally advanced esophageal cancer using 18F-FDG PET-CT imaging: a prospective cohort study. |
AC, CRT, LAEC, PPV, RD, SCC, TRG |
| 24 |
2023 |
Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysis. |
HR, nCRT, OR, OS |
| 25 |
2023 |
Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study. |
ER, FISH, HER2, HER2/CEP17, IHC, PgR, TNM |
| 26 |
2023 |
Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world. |
DCR, MPR, NSCLC, ORR |
| 27 |
2023 |
Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis. |
MPR, NICRT, NICT, TRAEs |
| 28 |
2023 |
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study. |
AJCC, BC, HER2, HR |
| 29 |
2023 |
Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. |
ER, HER2, NACT, PgR |
| 30 |
2023 |
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. |
EFS, HR, miRNAs |
| 31 |
2023 |
Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes. |
AA, BC, TME, TNBC |
| 32 |
2023 |
HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. |
BC, IHC, ISH, NACT, OS, RFS |
| 33 |
2023 |
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. |
CI, ctDNA, PFS, UC |
| 34 |
2023 |
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy. |
HR, NAC |
| 35 |
2023 |
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial. |
HRD |
| 36 |
2023 |
Impacts of HER2 Immunohistochemical Scores on Response and Outcomes of HER2-Positive Breast Cancers after Neoadjuvant Therapy. |
DFS, HER2, IHC, ISH, NST, OS |
| 37 |
2023 |
Integrated Intensified Chemoradiation in the Setting of Total Neoadjuvant Therapy (TNT) in Patients with Locally Advanced Rectal Cancer: A Retrospective Single-Arm Study on Feasibility and Efficacy. |
CONCT, CRT, DFS, ICT, LCRT, TNT |
| 38 |
2023 |
Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis. |
OS, PFS, TTS |
| 39 |
2023 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. |
BC, BCS, LRR, NAIs, NCT |
| 40 |
2023 |
Machine learning with textural analysis of longitudinal multiparametric MRI and molecular subtypes accurately predicts pathologic complete response in patients with invasive breast cancer. |
AUC, XGBoost |
| 41 |
2023 |
Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study. |
BC, MetS, NAC, NCEP ATP III |
| 42 |
2023 |
MRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. |
AUC, LARC, nCRT |
| 43 |
2023 |
Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. |
MPR, TLND |
| 44 |
2023 |
Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. |
ALK, CT, MPR, NGS, PCNB, PR |
| 45 |
2023 |
Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. |
AEs, DFS, ORR, TNBC |
| 46 |
2023 |
Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study. |
NAC, TN |
| 47 |
2023 |
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). |
AE, BC, EC, HER2, nab-PTX, NAC, Pmab, PR, RR, TILs, Tmab |
| 48 |
2023 |
Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. |
CI, HCC, ICIs, MPR, OR |
| 49 |
2023 |
Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma. |
EFS, LAEC, MPR, NCT, nICT, PTR, TRG |
| 50 |
2023 |
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. |
ESCC, MPR, TMB, TRAEs |
| 51 |
2023 |
Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. |
ICIs, MPR |
| 52 |
2023 |
Nipple-Sparing Mastectomy After Neoadjuvant Chemotherapy: Definitive Results with a Long-Term Follow-Up Evaluation. |
LRRs, NAC, NACT, NSM |
| 53 |
2023 |
Omission of axillary sentinel lymph node biopsy in early invasive breast cancer. |
BCS, NAST, SLNB |
| 54 |
2023 |
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. |
DTCs, IE/FC, NAC, RCB |
| 55 |
2023 |
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. |
BCR, CA, CR, DD, HR, ORR, OS, PD, PFS, RR, SD, TNBC |
| 56 |
2023 |
Pathological complete response and oncological outcomes in locally advanced breast cancers treated with neoadjuvant radiotherapy: an Australian perspective. |
NART |
| 57 |
2023 |
Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report. |
ICI, LACRC, NIT |
| 58 |
2023 |
Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study. |
AEs, DCR, ESCC, iPR, iSD, MPR, ORR, PFS |
| 59 |
2023 |
Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report. |
PCa, RP |
| 60 |
2023 |
Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer. |
NeoT |
| 61 |
2023 |
Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy. |
AEs, MRI, PBI, SABR |
| 62 |
2023 |
Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data. |
BCS, DFS, LNs, LVI, NAC, OS, ROC, SJTU-BCDB, US |
| 63 |
2023 |
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. |
AUCs, DCE, NAST, TNBC |
| 64 |
2023 |
Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer. |
ALNMs, NCT, SER |
| 65 |
2023 |
Predictive value of 18F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation. |
NAC, TLR, VOI |
| 66 |
2023 |
Predictive value of modified MRI-based split scar sign (mrSSS) score for pathological complete response after neoadjuvant chemoradiotherapy for patients with rectal cancer. |
DWI, mrSSS, mrTRG, nCRT, T2WI |
| 67 |
2023 |
Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer. |
AUC, DCA, ESCC, LASSO, nICT, ROC, SII |
| 68 |
2023 |
Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under "Real World" Conditions? |
DFS, nRCT, OS, PSM, pts |
| 69 |
2023 |
Prognostic analysis of three forms of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment. |
DFS, Ki-67B, Ki-67T, NST |
| 70 |
2023 |
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. |
CALGB, EFS, TILs |
| 71 |
2023 |
Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response. |
NAC, OS, RFS, TME, TNBC |
| 72 |
2023 |
Radiomic features derived from pretherapeutic MRI predict chemoradiation response in locally advanced rectal cancer. |
CRT, LARC, MR |
| 73 |
2023 |
Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC. |
aHR, aOR, EBC, OS, TNBC |
| 74 |
2023 |
Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients. |
ALND, LNTB, PST, RNI, RR, SLNB |
| 75 |
2023 |
STARD3: A New Biomarker in HER2-Positive Breast Cancer. |
NST |
| 76 |
2023 |
Strategies to Optimize Treatment for Locally Advanced Rectal Cancer. |
LARC |
| 77 |
2023 |
Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer. |
NAC, TME, TNBC |
| 78 |
2023 |
Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer. |
AUC, BC, TILs, TNBC |
| 79 |
2023 |
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. |
BC, CI, EFS, OS |
| 80 |
2023 |
Textural Analysis as a Predictive Biomarker in Rectal Cancer. |
CRC, MRTA, nCRT, TA |
| 81 |
2023 |
The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial. |
cCR, NAC |
| 82 |
2023 |
The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials. |
BC, CBR, DCR, DRFS, ET, IDFS, ORR, OS, PFS, RR |
| 83 |
2023 |
The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials. |
BC, RCTs, RR, ZA |
| 84 |
2023 |
The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study. |
AEs, bpCR, HER2, ORR, TKI |
| 85 |
2023 |
The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. |
DFS, FDG, mOS, PET/CT, PST |
| 86 |
2023 |
The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. |
BC, C-index, NAC, NLR, OS |
| 87 |
2023 |
The prognostic values of FOXP3+ tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis. |
CI, FOXP3+, HR, OR, OS, TILs, Treg |
| 88 |
2023 |
The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression. |
18F-FDG PET-CT, AUC, GR, LARC, nCRT, near-pCR, NPVs, PPVs, RI, TME |
| 89 |
2023 |
The Relationship among Bowel [18]F-FDG PET Uptake, Pathological Complete Response, and Eating Habits in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. |
BC, FDG, NAC, PET/CT |
| 90 |
2023 |
The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer. |
DFS, HER2, LABC, NAC |
| 91 |
2023 |
The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. |
CTAs, RCB, TNBCs |
| 92 |
2023 |
Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation. |
AUC, NAC, OR, PD, ROC, syMRI |
| 93 |
2023 |
Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series. |
AR, ARPIs, BED, P-SABR, t-NEPC |
| 94 |
2023 |
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. |
NAC, TNBC |
| 95 |
2023 |
Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. |
AUC, HDL-C, MPR, NCIO, NSCLC, OR, TC |
| 96 |
2023 |
Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response. |
EC, NST, PR |
| 97 |
2023 |
[Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer]. |
ECOG, IMRT, nCRT, SCRT-TNT, TME |
| 98 |
2022 |
"This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients". |
FNR, NACT, SNB |
| 99 |
2022 |
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer. |
CT, FDG, FOXP3, PD-1, PD-L1, PET, TIL, TIME, TNBC |
| 100 |
2022 |
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. |
10-miRNA RS, AUC, DFS, HER2, HR, NAC, PR |
|
A Search Service for Abbreviation / Long Form
